171 related articles for article (PubMed ID: 26031435)
1. PET imaging of DNA damage using (89)Zr-labelled anti-γH2AX-TAT immunoconjugates.
Knight JC; Topping C; Mosley M; Kersemans V; Falzone N; Fernández-Varea JM; Cornelissen B
Eur J Nucl Med Mol Imaging; 2015 Oct; 42(11):1707-1717. PubMed ID: 26031435
[TBL] [Abstract][Full Text] [Related]
2.
Poty S; Mandleywala K; O'Neill E; Knight JC; Cornelissen B; Lewis JS
Theranostics; 2020; 10(13):5802-5814. PubMed ID: 32483420
[No Abstract] [Full Text] [Related]
3. Imaging DNA damage in vivo using gammaH2AX-targeted immunoconjugates.
Cornelissen B; Kersemans V; Darbar S; Thompson J; Shah K; Sleeth K; Hill MA; Vallis KA
Cancer Res; 2011 Jul; 71(13):4539-49. PubMed ID: 21586614
[TBL] [Abstract][Full Text] [Related]
4. Amplification of DNA damage by a γH2AX-targeted radiopharmaceutical.
Cornelissen B; Darbar S; Kersemans V; Allen D; Falzone N; Barbeau J; Smart S; Vallis KA
Nucl Med Biol; 2012 Nov; 39(8):1142-51. PubMed ID: 22819196
[TBL] [Abstract][Full Text] [Related]
5. Molecular radiotherapy using cleavable radioimmunoconjugates that target EGFR and γH2AX.
Cornelissen B; Waller A; Able S; Vallis KA
Mol Cancer Ther; 2013 Nov; 12(11):2472-82. PubMed ID: 23963362
[TBL] [Abstract][Full Text] [Related]
6. Positron-Emission Tomography of HER2-Positive Breast Cancer Xenografts in Mice with
Al-Saden N; Lam K; Chan C; Reilly RM
Mol Pharm; 2018 Aug; 15(8):3383-3393. PubMed ID: 29957952
[TBL] [Abstract][Full Text] [Related]
7.
Knight JC; Mosley MJ; Bravo LC; Kersemans V; Allen PD; Mukherjee S; O'Neill E; Cornelissen B
Clin Cancer Res; 2017 Nov; 23(21):6498-6504. PubMed ID: 28774899
[No Abstract] [Full Text] [Related]
8. Preclinical 89Zr Immuno-PET of High-Grade Serous Ovarian Cancer and Lymph Node Metastasis.
Sharma SK; Sevak KK; Monette S; Carlin SD; Knight JC; Wuest FR; Sala E; Zeglis BM; Lewis JS
J Nucl Med; 2016 May; 57(5):771-6. PubMed ID: 26837339
[TBL] [Abstract][Full Text] [Related]
9. Dual-isotope imaging allows in vivo immunohistochemistry using radiolabelled antibodies in tumours.
Knight JC; Mosley MJ; Kersemans V; Dias GM; Allen PD; Smart S; Cornelissen B
Nucl Med Biol; 2019 Mar; 70():14-22. PubMed ID: 30825614
[TBL] [Abstract][Full Text] [Related]
10. Quantitative PET imaging of Met-expressing human cancer xenografts with 89Zr-labelled monoclonal antibody DN30.
Perk LR; Stigter-van Walsum M; Visser GW; Kloet RW; Vosjan MJ; Leemans CR; Giaccone G; Albano R; Comoglio PM; van Dongen GA
Eur J Nucl Med Mol Imaging; 2008 Oct; 35(10):1857-67. PubMed ID: 18491091
[TBL] [Abstract][Full Text] [Related]
11. A comparison of DFO and DFO* conjugated to trastuzumab-DM1 for complexing
Cho H; Al-Saden N; Lam H; Möbus J; Reilly RM; Winnik MA
Nucl Med Biol; 2020; 84-85():11-19. PubMed ID: 31931305
[TBL] [Abstract][Full Text] [Related]
12. DNA double-strand break repair: a theoretical framework and its application.
Murray PJ; Cornelissen B; Vallis KA; Chapman SJ
J R Soc Interface; 2016 Jan; 13(114):20150679. PubMed ID: 26819332
[TBL] [Abstract][Full Text] [Related]
13.
Price EW; Carnazza KE; Carlin SD; Cho A; Edwards KJ; Sevak KK; Glaser JM; de Stanchina E; Janjigian YY; Lewis JS
J Nucl Med; 2017 Sep; 58(9):1386-1394. PubMed ID: 28280216
[TBL] [Abstract][Full Text] [Related]
14. In vivo monitoring of intranuclear p27(kip1) protein expression in breast cancer cells during trastuzumab (Herceptin) therapy.
Cornelissen B; Kersemans V; McLarty K; Tran L; Vallis KA; Reilly RM
Nucl Med Biol; 2009 Oct; 36(7):811-9. PubMed ID: 19720293
[TBL] [Abstract][Full Text] [Related]
15. Zr-89 Immuno-PET Targeting Ectopic ATP Synthase Enables In-Vivo Imaging of Tumor Angiogenesis.
Park BN; Kim GH; Ko SA; Shin GH; Lee SJ; An YS; Yoon JK
Int J Mol Sci; 2019 Aug; 20(16):. PubMed ID: 31412537
[TBL] [Abstract][Full Text] [Related]
16.
Fung K; Vivier D; Keinänen O; Sarbisheh EK; Price EW; Zeglis BM
Molecules; 2020 May; 25(10):. PubMed ID: 32429033
[TBL] [Abstract][Full Text] [Related]
17. Direct comparison of the in vitro and in vivo stability of DFO, DFO* and DFOcyclo* for
Raavé R; Sandker G; Adumeau P; Jacobsen CB; Mangin F; Meyer M; Moreau M; Bernhard C; Da Costa L; Dubois A; Goncalves V; Gustafsson M; Rijpkema M; Boerman O; Chambron JC; Heskamp S; Denat F
Eur J Nucl Med Mol Imaging; 2019 Aug; 46(9):1966-1977. PubMed ID: 31161258
[TBL] [Abstract][Full Text] [Related]
18. Immuno-PET Imaging of CD30-Positive Lymphoma Using 89Zr-Desferrioxamine-Labeled CD30-Specific AC-10 Antibody.
Rylova SN; Del Pozzo L; Klingeberg C; Tönnesmann R; Illert AL; Meyer PT; Maecke HR; Holland JP
J Nucl Med; 2016 Jan; 57(1):96-102. PubMed ID: 26514172
[TBL] [Abstract][Full Text] [Related]
19. Immuno-PET Imaging of the Programmed Cell Death-1 Ligand (PD-L1) Using a Zirconium-89 Labeled Therapeutic Antibody, Avelumab.
Jagoda EM; Vasalatiy O; Basuli F; Opina ACL; Williams MR; Wong K; Lane KC; Adler S; Ton AT; Szajek LP; Xu B; Butcher D; Edmondson EF; Swenson RE; Greiner J; Gulley J; Eary J; Choyke PL
Mol Imaging; 2019; 18():1536012119829986. PubMed ID: 31044647
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]